Tirofiban counteracts endothelial cell apoptosis through the VEGF/VEGFR2/pAkt axis

Giordano, Arturo; Romano, Simona; Dilhas, Anna; Corcione, Nicola; Messina, Stefano; Avellino, Raffaella; Biondi‐Zoccai, Giuseppe; Ferraro, Paolo; Romano, Maria

doi:10.1016/j.vph.2015.12.001

Cited by 21 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are two possible ways to identify and characterize EPCs: by flow cytometry, looking at cell surface antigenic markers; and by cell culture methods, looking at their functional activities (reviewed in [37]). Currently, 3 main cell culture methods are used to identify 3 types of EPCs with different functions and angiogenic potential: late outgrowth colonies, also known as ECFCs, which are considered as genuine or true EPCs [30]; colony-forming unit (CFU)-Hill cells [28]; and early outgrowth EPCs, also known as circulating angiogenic cells (CACs) [38] (reviewed in [37]).…”

Section: Discussionmentioning

confidence: 99%

“…Currently, 3 main cell culture methods are used to identify 3 types of EPCs with different functions and angiogenic potential: late outgrowth colonies, also known as ECFCs, which are considered as genuine or true EPCs [30]; colony-forming unit (CFU)-Hill cells [28]; and early outgrowth EPCs, also known as circulating angiogenic cells (CACs) [38] (reviewed in [37]). ECFCs display a high proliferative potential, express endothelial antigens, form capillary-like structures when plated on Matrigel, but also blood vessels when suspended in collagen or Matrigel scaffolds and implanted in immunodeficient mice (reviewed in [37]). CFU-Hill cells and CACs display a low proliferative potential, but a great potential to secrete an array of angiogenic cytokines.…”

Section: Discussionmentioning

confidence: 99%

“…CFU-Hill cells and CACs display a low proliferative potential, but a great potential to secrete an array of angiogenic cytokines. CFU-Hill cells and CACs are positive for CD45, CD34, CD31 and KDR, and have the capacity to uptake uptake acetylated LDL labeled with 1,1’-dioctadecyl-3, 3, 3’, 3’-tetramethyl-indocarbocyanine perchlorate (DiDLDL)) [37]. As to the identification and enumeration of EPCs by flow cytometry, EPC antigenic profile continues to be controversial [33, 39], and no consensus guidelines have been agreed upon so far [39, 40].…”

Section: Discussionmentioning

confidence: 99%

“…Similarly as for EPCs, CEC characterization and enumeration in the bloodstream has been proposed as a potential biomarker of the response to treatment in several clinical conditions involving vascular damage, regeneration and growth [4, 41, 45–47]. Likewise, preclinical and clinical studies have suggested that EPCs play an essential role in neovascularization, and are biomarkers of atherosclerosis, inversely related to the presence and progression of the disease (reviewed in [37]).The balance of CEC and EPC levels would reflects the endothelial health status [43, 48]. …”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease—The REMEDY-EPC early substudy

et al. 2017

View full text Add to dashboard Cite

Rationale and objectiveEndothelial progenitor cells (EPCs) play a role in vascular repair, while circulating endothelial cells (CECs) are biomarkers of vascular damage and regeneration. Statins may promote EPC/CEC mobilization in the peripheral blood. We evaluated whether pre-procedural exposure to different lipid-lowering drugs (statins±ezetimibe) can acutely increase levels/activity of EPCs/CECs in patients with stable coronary artery disease (CAD).MethodsIn a planned sub-analysis of the Rosuvastatin For REduction Of Myocardial DamagE During Coronary AngioplastY (REMEDY) trial, 38 patients with stable CAD on chronic low-dose statin therapy were randomized, in a double-blind, placebo-controlled design, into 4 groups before PCI: i. placebo (n = 11); ii. atorvastatin (80 mg+40 mg, n = 9); iii. rosuvastatin (40 mg twice, n = 9); and iv. rosuvastatin (5 mg) and ezetimibe (10 mg) twice, (n = 9). At baseline and 24 h after treatment–before PCI–, patients underwent blinded analyses of EPCs [colony forming units-endothelial cells (CFU-ECs), endothelial colony-forming cells (ECFCs) and tubulization activity] and CECs in peripheral blood.ResultsWe found no significant treatment effects on parameters investigated such as number of CECs [Median (IQR): i. 0(0), ii. 4.5(27), iii. 1.9(2.3), iv. 1.9(2.3)], CFU-ECs [Median (IQR): i. 27(11), ii. 19(31), iii. 47(36), iv. 30(98)], and ECFCs [Median (IQR): i. 86(84), ii. 7(84), iii. 8/(42.5), iv. 5(2)], as well as tubulization activity [total tubuli (well), Median (IQR): i. 19(7), ii. 5(4), iii. 25(13), iv. 15(24)].ConclusionsIn this study, we found no evidence of acute changes in levels or activity of EPCs and CECs after high-dose lipid-lowering therapy in stable CAD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease—The REMEDY-EPC early substudy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Tirofiban also stimulates VEGF expression and promotes proliferation of endothelial cells. VEGF is a well known inhibitor of endothelial cell apoptosis 5 .…”

Section: Introductionmentioning

confidence: 99%

Untitled

2017

IJPSR

View full text Add to dashboard Cite

ABSTRACT:We studied the feasibility, safety, clinical benefit, efficacy and 30 day outcome in 50 patients receiving tirofiban in patients with failed thrombolysis in acute ST elevation myocardial infarction, and compared with 50 patients for age, gender and infarct location, who did not receive rescue treatment for different reasons. Tirofiban resulted in an overall ST segment elevation, resolution, at 240 minutes in 44 patients (88 %). Incidence of major events during hospitalization was higher in control group. One patient (2 %) died in study group against 4(8%) in control group while 4 patients had refractory angina needing early percutaneous coronary intervention as compared to 13 in control group. None reinfarcted as against 4 in control group. Two patients developed congestive heart failure against 8 in control group. However, minor bleeding events (mainly gum) were significantly higher, 9 against 0 in control group. Coronary angiography revealed residual thrombus only in 4 patients treated with tirofiban compared to 13 in controls and surprisingly the number of stents required were less in study group (74 % i.e. 37 patients) against (96 % i.e. 48 patients) in control group. On 30 day follow up no death, congestive heart failure or repeat revascularization procedure was recorded in the study group with significant improvement in left ventricular ejection fraction, while as there were 3 deaths and 4 patients had congestive heart failure in control group INTRODUCTION: Success rate of intravenous thrombolysis is close to 70 %. Therefore stratigies for failed thrombolysis or reocclusion/ reinfarction also need to be planned in advance. Ongoing chest pain, non-resolution of ECG i.e. failure of the elevated ST segment to fall by 50% or more in lead with maximal ST elevation recorded 90 minutes after onset of thrombolysis, hemodynamic or electric instability indicate failure of recanalization. Repeat thrombolysis with the same or other agent is not to be practiced.

show abstract

Key Roles of RGD-Recognizing Integrins During Cardiac Development, on Cardiac Cells, and After Myocardial Infarction

Schussler

Chachques²,

Alifano

et al. 2021

J. of Cardiovasc. Trans. Res.

View full text Add to dashboard Cite

Tirofiban counteracts endothelial cell apoptosis through the VEGF/VEGFR2/pAkt axis

Cited by 21 publications

References 27 publications

The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease—The REMEDY-EPC early substudy

The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease—The REMEDY-EPC early substudy

Untitled

Key Roles of RGD-Recognizing Integrins During Cardiac Development, on Cardiac Cells, and After Myocardial Infarction

Contact Info

Product

Resources

About